LymphedemaV1, Main, Exploration, bibRecord, 001569

[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].

Identifieur interne : 001569 ( Main/Exploration ); précédent : 001568; suivant : 001570

[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].

Auteurs : Lukáš Hnátek

Source :

Vnitrni lekarstvi [ 0042-773X ] ; 2015.

RBID : pubmed:26465280

Descripteurs français

KwdFr :
- Diosmine (usage thérapeutique), Europe, Hespéridine (usage thérapeutique), Humains, Hémorroïdes (traitement médicamenteux), Insuffisance veineuse (traitement médicamenteux), Lymphoedème (traitement médicamenteux), Maladie chronique, Microcirculation (), Résultat thérapeutique, Ulcère variqueux (traitement médicamenteux).
MESH :
- traitement médicamenteux : Hémorroïdes, Insuffisance veineuse, Lymphoedème, Ulcère variqueux.
- usage thérapeutique : Diosmine, Hespéridine.
- Europe, Humains, Maladie chronique, Microcirculation, Résultat thérapeutique.

English descriptors

KwdEn :
- Chronic Disease, Diosmin (therapeutic use), Europe, Hemorrhoids (drug therapy), Hesperidin (therapeutic use), Humans, Lymphedema (drug therapy), Microcirculation (drug effects), Treatment Outcome, Varicose Ulcer (drug therapy), Venous Insufficiency (drug therapy).
MESH :
- chemical , therapeutic use : Diosmin, Hesperidin.
- geographic : Europe.
- drug effects : Microcirculation.
- drug therapy : Hemorrhoids, Lymphedema, Varicose Ulcer, Venous Insufficiency.
- Chronic Disease, Humans, Treatment Outcome.

Abstract

Chronic venous disorder (CVD) is a common illness with high incidence existing especially in Europe and North America. The main goal of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin is to eliminate the symptoms of CVD (venous pain, fatigue, etc). But MPFF of diosmin and hesperidin has good effectiveness for treatment of venous oedema and venous ulcer too. There are many papers that prove its effectiveness in the experiment and in the microcirculation too. The other indications for MPFF of diosmin hesperidin is hemorrhoidal disease and the accessory treatment of lymphedema. It is proved that this substance could be used as an effective supplementary treatment of symptoms after venous intervention. Only MPFF diosmin and hesperidin received the best recommendation - 1B in the last guidelines for VAD therapy.

PubMed: 26465280

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].</title>
<author><name sortKey="Hnatek, Lukas" sort="Hnatek, Lukas" uniqKey="Hnatek L" first="Lukáš" last="Hnátek">Lukáš Hnátek</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26465280</idno>
<idno type="pmid">26465280</idno>
<idno type="wicri:Area/PubMed/Corpus">000B87</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B87</idno>
<idno type="wicri:Area/PubMed/Curation">000B87</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B87</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B87</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B87</idno>
<idno type="wicri:Area/Ncbi/Merge">007A21</idno>
<idno type="wicri:Area/Ncbi/Curation">007A21</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">007A21</idno>
<idno type="wicri:doubleKey">0042-773X:2015:Hnatek L:therapeutic:potential:of</idno>
<idno type="wicri:Area/Main/Merge">001571</idno>
<idno type="wicri:Area/Main/Curation">001569</idno>
<idno type="wicri:Area/Main/Exploration">001569</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].</title>
<author><name sortKey="Hnatek, Lukas" sort="Hnatek, Lukas" uniqKey="Hnatek L" first="Lukáš" last="Hnátek">Lukáš Hnátek</name>
</author>
</analytic>
<series><title level="j">Vnitrni lekarstvi</title>
<idno type="ISSN">0042-773X</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chronic Disease</term>
<term>Diosmin (therapeutic use)</term>
<term>Europe</term>
<term>Hemorrhoids (drug therapy)</term>
<term>Hesperidin (therapeutic use)</term>
<term>Humans</term>
<term>Lymphedema (drug therapy)</term>
<term>Microcirculation (drug effects)</term>
<term>Treatment Outcome</term>
<term>Varicose Ulcer (drug therapy)</term>
<term>Venous Insufficiency (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diosmine (usage thérapeutique)</term>
<term>Europe</term>
<term>Hespéridine (usage thérapeutique)</term>
<term>Humains</term>
<term>Hémorroïdes (traitement médicamenteux)</term>
<term>Insuffisance veineuse (traitement médicamenteux)</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Maladie chronique</term>
<term>Microcirculation ()</term>
<term>Résultat thérapeutique</term>
<term>Ulcère variqueux (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diosmin</term>
<term>Hesperidin</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microcirculation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemorrhoids</term>
<term>Lymphedema</term>
<term>Varicose Ulcer</term>
<term>Venous Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémorroïdes</term>
<term>Insuffisance veineuse</term>
<term>Lymphoedème</term>
<term>Ulcère variqueux</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diosmine</term>
<term>Hespéridine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Europe</term>
<term>Humains</term>
<term>Maladie chronique</term>
<term>Microcirculation</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic venous disorder (CVD) is a common illness with high incidence existing especially in Europe and North America. The main goal of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin is to eliminate the symptoms of CVD (venous pain, fatigue, etc). But MPFF of diosmin and hesperidin has good effectiveness for treatment of venous oedema and venous ulcer too. There are many papers that prove its effectiveness in the experiment and in the microcirculation too. The other indications for MPFF of diosmin hesperidin is hemorrhoidal disease and the accessory treatment of lymphedema. It is proved that this substance could be used as an effective supplementary treatment of symptoms after venous intervention. Only MPFF diosmin and hesperidin received the best recommendation - 1B in the last guidelines for VAD therapy.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Hnatek, Lukas" sort="Hnatek, Lukas" uniqKey="Hnatek L" first="Lukáš" last="Hnátek">Lukáš Hnátek</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001569 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001569 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26465280
   |texte=   [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26465280" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].

[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.